For years, people with rheumatoid arthritis (RA) were told to live with pain, stiffness, and fatigue. Doctors adjusted meds slowly, hoping symptoms would settle down on their own. But that approach didn’t stop joint damage. Today, there’s a better way - and it’s not magic. It’s called treat-to-target (T2T). This isn’t just a buzzword. It’s a proven, structured plan that gets people into remission - and keeps them there.
What Does Remission Even Mean in Rheumatoid Arthritis?
Remission doesn’t mean you’re cured. It means your disease is so quiet, you might forget you have RA. No swollen joints. No morning stiffness lasting more than 15 minutes. No fatigue dragging you down. Blood tests show normal inflammation levels. X-rays don’t show new damage. You can walk, lift, and live without pain holding you back.
The standard way to measure this is the DAS28 score - a number based on 28 joints checked by your doctor, your blood inflammation markers (CRP or ESR), and how you’re feeling. A score below 2.6 is remission. Between 2.6 and 3.2? That’s low disease activity - still good, but not quite there. Most people don’t realize: if you’re not measuring this regularly, you’re flying blind.
How Treat-to-Target Changed Everything
Before T2T, treatment was reactive. If you came in with a flare, your doctor might bump up your dose. If you felt okay, they’d leave things alone. No set goals. No schedule. No accountability.
T2T flipped that. It says: Let’s pick a target - remission or low disease activity - and get there as fast as possible. If you’re not improving in 3 months, we change the plan. Not next visit. Not next year. Three months. That’s it.
The evidence is overwhelming. In the DREAM trial, 47% of people with early RA reached remission at 6 months using T2T. At 12 months? 58%. In the BeSt trial, 61% were in remission after two years with T2T. Compare that to routine care - only 37% reached the same point. The difference? Structure. Speed. Consistency.
The Step-by-Step Treatment Escalation Plan
T2T isn’t about throwing everything at you at once. It’s a ladder. You start at the bottom and climb only if you need to.
- Methotrexate - First line. Usually 10-25 mg per week. Cheap. Effective. Often the only thing you need.
- Triple Therapy - If methotrexate alone isn’t enough, add sulfasalazine and hydroxychloroquine. Works well for many. Fewer side effects than biologics.
- Biologics - If that fails, you move to biologics: TNF blockers like adalimumab or etanercept, IL-6 inhibitors like tocilizumab, or JAK inhibitors like baricitinib. These target specific parts of the immune system causing the damage.
Every 1-3 months, your doctor checks your DAS28. If you’re not moving toward remission, you step up. No waiting. No guessing. No hoping.
It’s Not Just About Drugs - It’s About Measurement
Here’s the hard truth: if your doctor isn’t measuring your disease activity every visit, you’re not getting T2T.
A 2020 survey found only 58% of rheumatologists use standardized scores like DAS28 at every appointment. That’s not T2T. That’s guesswork.
Real T2T means:
- DAS28, CDAI, or SDAI score calculated at every visit
- Clear target set with you - remission or low disease activity
- Medication changes if target isn’t met in 3 months
- Regular blood tests for CRP/ESR
- Joint counts done properly - not just a quick glance
Some clinics use electronic templates that auto-calculate your score. Others have nurses handle the measurements. Either way, if it’s not documented and tracked, it’s not happening.
What Patients Say - Real Stories, Real Results
On patient forums, people who’ve had T2T tell the same story:
“I had RA for 3 years. Nothing worked. Then I switched to a rheumatologist who used DAS28 every 6 weeks. I was in remission by month 6. I haven’t had a flare since.” - Reddit, March 2023
But there’s another side:
“My doctor says she does T2T, but she only checks my CRP once a year. What’s the point?” - HealthUnlocked, July 2022
And:
“I did everything right. Took my meds. Came to every appointment. Still didn’t hit remission. Felt like a failure.” - MyRheumaTeam, November 2022
That last one matters. Not everyone reaches remission. And that’s okay. T2T isn’t about perfection. It’s about progress. For some, low disease activity is the win. For others, staying off steroids or avoiding joint surgery is the goal. The key is having the conversation - and setting a goal together.
Why T2T Works Better Than Routine Care
Let’s compare two people with RA:
- Person A - Sees their doctor every 6 months. Meds are changed only when they’re in obvious pain. No scores. No plan.
- Person B - Sees their rheumatologist every 8 weeks. DAS28 is calculated. Target is remission. If no improvement in 3 months, meds change.
After 12 months, Person B is far more likely to be in remission. Why? Because damage happens fast. In the first year, RA can destroy cartilage and bone. T2T stops that before it starts. The CAMERA-II trial showed 50% remission with T2T vs. 28% with routine care - after just two years.
It’s not just about feeling better. It’s about keeping your hands, knees, and spine intact. People on T2T have less joint damage on X-rays. They’re more likely to keep working. Less likely to need surgery.
The Hidden Hurdles - Why T2T Isn’t Everywhere
Despite the evidence, T2T isn’t standard everywhere. Why?
- Time - Calculating DAS28 takes 5-10 minutes. Most clinics are booked every 15 minutes.
- Training - Not all doctors know how to count joints properly or interpret scores.
- Access - Biologics and JAK inhibitors cost thousands. Insurance won’t always cover them without trying cheaper options first.
- Communication - A 2022 study found only 40.8% of rheumatologists and patients agreed on treatment goals. If you don’t know the target, you can’t reach it.
Solutions? Electronic tools that auto-calculate scores. Nurse-led monitoring. Patient education. Some clinics now use apps like the ACR’s Treat to Target app - downloaded over 15,000 times. These help patients track symptoms and prep for visits.
What’s Next? The Future of RA Treatment
T2T isn’t static. It’s evolving.
The 2022 EULAR guidelines now say: targets can be individualized. If remission isn’t possible, low disease activity is fine. If your priority is sleeping through the night or playing with your grandkids, that’s the goal.
Researchers are testing digital tools - smartphone apps that track pain, swelling, and fatigue daily. The DART trial is testing whether this real-time data can guide treatment faster than monthly visits.
Down the road, we may use blood tests that predict which drug will work for you before you even start. Imagine knowing your best option before you take your first pill. That’s the next frontier.
What You Can Do Right Now
If you have RA, here’s your action plan:
- Ask your rheumatologist: “What’s my DAS28 score?” If they don’t know, ask why not.
- Set a clear goal: “Is the target remission or low disease activity?”
- Ask: “What’s our plan if I’m not improving in 3 months?”
- Track your own symptoms - pain, stiffness, fatigue - between visits.
- Use the ACR Treat to Target app or the T2T-Rheuma website (free tools with guides in 12 languages).
You don’t have to accept pain as normal. You don’t have to wait for your joints to break before something changes. T2T works. It’s not perfect. But it’s the best tool we have.
Remission isn’t a miracle. It’s a measurable outcome. And with the right plan, it’s within reach.
Write a comment